initial therapeutics, inc.
285 east grand avenue
south san francisco, ca 94080

news & publications

news

With $75 Million from Apple Tree Partners, Initial Therapeutics Launches to Create a New Kind of Drug Designed to Stop the Formation of Difficult-to-Drug Protein Targets

May 1, 2023

publications

Wenfei Li, Fred R. Ward, Kim F. McClure, Stacey Tsai-Lan Chang, Elizabeth Montabana, Spiros Liras, Robert G. Dullea, and Jamie H. D. Cate. Structural basis for selective stalling of human ribosome nascent chain complexes by a drug-like molecule. Nat Struct Mol Biol 26, 501–509 (2019).

Nadège Liaud, Max A. Horlbeck, Luke A. Gilbert, Ketrin Gjoni, Jonathan S. Weissman, and Jamie H. D. Cate. Cellular Response To Small Molecules That Selectively Stall Protein Synthesis By The Ribosome. Plos Genet 15, e1008057 (2019).

Nathanael G. Lintner, Kim F McClure, Donna Petersen, Allyn T. Londregan, David W Piotrowski, Liuqing Wei, Jun Xiao, Michael Bolt, Paula M. Loria, Bruce Maguire, Kieran F. Geoghegan, Austin Huang, Tim Rolph, Spiros Liras, Jennifer A. Doudna, Robert G Dullea, and Jamie H. D Cate. Selective Stalling Of Human Translation Through Small-Molecule Engagement Of The Ribosome Nascent Chain. Plos Biol 15, e2001882 (2017).